Date:3/6/2013

ur licensees that may generate royalty and milestone payments to us, our ability to achieve product sales and royalties, competition, our dependence on other companies to commercialize, manufacture and sell products using our technologies and our ability to enter into favorable new agreements with such companies, our ability to cut expenses and maintain efficiencies, our ability to enter into new financing arrangements,  the ability of our products to gain market acceptance and increase market share, the uncertainty of results of animal and human testing, the risk of product liability and liability for human clinical trials, our dependence on patents and other proprietary rights and the risks associated with patent litigation, dependence on key management officials, the availability and cost of capital, the availability of qualified personnel, changes in, or the failure to comply with, governmental regulations, general economic and business conditions, our history of losses and ability to achieve profitability, litigation and other risk factors discussed in our Securities and Exchange Commission ("SEC") filings, including our annual report on Form 10-K and our quarterly reports on Form 10-Q. Words such as "anticipates," "expects," "intends," "plans," "predicts," "believes," "seeks," "estimates," "may," "will," "should," "would," "potential," "continue," and variations of these words (or negatives of these words) or similar expressions, are intended to identify forward-looking statements, but are not the exclusive means of identifying forward-looking statements. In addition, any statements that refer to expectations, projections, contingencies, goals, targets or other characterizations of future events or circumstances, including any underlying assumptions, are forward-looking statements and are not statements of historical fact. Except as required by applicable law, including the securities laws of the United States and the rules and r
'/>"/>

SOURCE Unigene Laboratories, Inc. Copyright©2012 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4
Related biology technology :

1. Unigene to Announce Fourth Quarter and Full-Year 2011 Financial Results on March 8, 2012
2. Unigene Receives 2012 Drug Delivery Partnerships Industry Achievement Award
3. Unigenes 2011 Year in Review - Key Elements in Place to Address Debt in 2012
4. Unigene to Present at the Oppenheimer 22nd Annual Healthcare Conference on December 13, 2011
5. A New way to Battle Acne? NPR says “Cut the Carbs”: Probiotic Action Comments on the Recent News
6. Probiotic Action Comments on New Findings on Using Light Therapy to Fight Acne
7. Acne Treatment Brand, Probiotic Action, Comments on the Use of a Virus to Treat Acne
8. Probiotic Comments on Claims that Plant-Based Oils Are the Best Acne Treatments
9. Probiotic Action Comments on Huffington Post’s, Best Foods for Acne and offers Advice on Foods to Balance your Body
10. An article from Bloomberg.com discusses Ban on a Common Acne Treatment; Probiotic Action Comments On the product Ban
11. Can You Be Too Old for Acne? Probiotic Action comments on news from The Vitals Blog